A Study of Ketamine in Patients With Treatment-resistant Depression
NCT01627782 · Janssen Research & Development, LLC
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 15
Measured over Baseline (Day 1) and Day 15
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
13 study sites
| Facility | City | Region | Country |
|---|---|---|---|
| — | Birmingham | Alabama | United States |
| — | Little Rock | Arkansas | United States |
| — | Centennial | Colorado | United States |
| — | Hartford | Connecticut | United States |
| — | New Haven | Connecticut | United States |
| — | Atlanta | Georgia | United States |
| — | Rockville | Maryland | United States |
| — | Marlton | New Jersey | United States |
| — | New York | New York | United States |
| — | Allentown | Pennsylvania | United States |
| — | Charleston | South Carolina | United States |
| — | Dallas | Texas | United States |
| — | Salt Lake City | Utah | United States |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT01627782 on ClinicalTrials.gov →
Last updated in the registry 2025-04-29. Registry records change; this page reflects the data build of 2026-08-25.
Related